Qualified Meetings With Biotech Decision-Makers. Delivered.

Your BDR reaches the Head of Business Development at a biotech that just closed its Series A and is six months into a Phase I trial. They take the call, engage across two meetings, and then go dark. The reason: their board froze all non-essential vendor spend until Phase I endpoints are hit. Your product was right. Your value proposition landed. But the timing was six months too early and no one on your team knew to ask about their trial timeline before investing four weeks in the conversation. You spent a quarter chasing a deal that was structurally impossible to close at that moment.

We map each target account's development stage before outreach begins. We use ClinicalTrials.gov, pipeline intelligence databases, and public funding data to identify which companies are approaching Phase II transitions, preparing regulatory submissions, or entering commercial build-out - the three windows where budget and mandate reliably align. You only enter conversations where the timing matches, not just the title.

You send a sequence to a Chief Scientific Officer at a mid-size oncology company. The first email opens with a benefit statement about accelerating their research pipeline. The CSO reads it as a vendor who does not understand the difference between a research platform and a clinical asset. The delete reflex fires before they reach your value proposition. Your product genuinely solves a real problem for their team. But the language you used positioned you as someone who has never read an IND filing, and in a sector where scientific credibility is the price of admission, that first impression is the only one you get.

We write sequences that use the vocabulary of the specific scientific and clinical function your product serves. If you are selling to clinical operations, we reference the challenges of managing multi-site trial complexity and data lock timelines. If you are selling to regulatory affairs, we anchor in submission cycle pressure and post-approval surveillance workloads. One sentence that sounds like it came from someone who has sat in that function opens doors that generic commercial language locks permanently.

Your team reached the Head of Commercial at a growth-stage biotech eight months ago. The conversation went well. They asked for a formal proposal. Two months later, procurement stepped in with a preferred vendor list your company was not on. Your contact then left for another role. The deal is technically still open in your CRM but there is no active champion, the procurement process reset, and you have no visibility into where it stands. You did everything right in the sales conversation. The process killed the deal because you were building a relationship with one person at the table instead of the full committee.

We map the full buying committee before outreach begins: the scientific or clinical champion, the commercial decision-maker, and the procurement or legal contact who will eventually gate the deal. Where possible we establish parallel relationships across the committee before a formal evaluation begins so that a single departure does not collapse the pipeline. Every meeting handoff includes the full stakeholder map and the procurement context we have already surfaced so your team can manage the committee, not just the champion.

You built a single outbound sequence and sent it to everyone with a Director or VP title across your target biotech accounts. The VP of Business Development and the VP of Clinical Operations both received the same email. The BD leader read it and forwarded it to R&D. The R&D lead was confused because half the message did not apply to their function. Neither replied. The problem was not your product. It was that one message trying to serve two completely different functional audiences served neither. In a sector where professional scepticism runs high and inboxes are guarded, ambiguity reads as ignorance, and the conversation ends before it starts.

We segment your target contacts by function before any sequence is written. Business Development and Licensing contacts receive sequences focused on partnership value and commercial acceleration timelines. Clinical Operations leads receive sequences focused on trial efficiency and data integrity. Regulatory Affairs contacts receive sequences anchored in submission deadlines and compliance workflows. Each persona gets language that speaks precisely to their objectives, not a catch-all message that fits no one well enough to generate a reply.